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Infections with hepatitis C virus (HCV) and, possibly, hepatitis B virus (HBV) are associated with an increased risk of non-Hodgkin’s
lymphoma (NHL) in the general population, but little information is available on the relationship between hepatitis viruses and NHL
among people with HIV (PHIV). We conducted a matched case–control study nested in the Swiss HIV Cohort Study (SHCS). Two
hundred and ninety-eight NHL cases and 889 control subjects were matched by SHCS centre, gender, age group, CD4þ count at
enrolment, and length of follow-up. Odds ratios (OR) and corresponding 95% confidence intervals (CI) were computed using logistic
regression to evaluate the association between NHL and seropositivity for antibodies against HCV (anti-HCV) and hepatitis B core
antigen (anti-HBc), and for hepatitis B surface antigen (HBsAg). Anti-HCV was not associated with increased NHL risk overall
(OR¼ 1.05; 95% CI: 0.63–1.75), or in different strata of CD4þ count, age or gender. Only among men having sex with men was an
association with anti-HCV found (OR¼ 2.37; 95% CI: 1.03–5.43). No relationships between NHL risk and anti-HBc or HBsAg
emerged. Coinfection with HIV and HCV or HBV did not increase NHL risk compared to HIV alone in the SHCS.
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People infected with HIV (PHIV) have an approximately 100-fold
increased risk of non-Hodgkin’s lymphoma (NHL), mainly high-
grade B-cell NHL, compared to the general population (Dal Maso
and Franceschi, 2003). The role of HIV seems to be indirect and
related to the effect of the virus on immunoregulation. Conversely,
the causal role of oncogenic viruses such as Epstein– Barr virus
(EBV) and, in much rarer instances, Kaposi’s sarcoma herpes virus
in the onset of NHL in PHIV is well established (Jaffe et al, 2001).
An association between hepatitis C virus (HCV) infection and
NHL in the general population has emerged in the last decade
(Gasparotto et al, 2002; Negri et al, 2004) and a meta-analysis of 17
studies from eight countries has shown a pooled relative risk of 2.5
(95% confidence interval (CI): 2.1–3.0) (Dal Maso and Franceschi,
in press).
Owing to shared routes of transmission, HCV and HIV
coinfection is common and is associated with higher HCV RNA
levels and increased risk of progression of HCV-related liver
disease than in the presence of HCV infection alone (Sulkowski
et al, 2000). Some investigators also attempted to evaluate whether
coinfection with HCV increased the risk of NHL among PHIV, but
did not find any association (Besson et al, 1999; Levine et al, 1999;
Engels et al, 2002; de Sanjose´ et al, 2004; Waters et al, 2005). None
of these studies, however, included more than 12 cases of NHL
positive for both HIV and HCV (Besson et al, 1999; Levine et al,
1999; de Sanjose´ et al, 2004; Waters et al, 2005).
We have therefore, carried out a much larger case–control study
nested in the Swiss HIV Cohort Study (SHCS) to assess the
relationship between HCV infection and NHL in PHIV. On account
of some reports of increased NHL risk in HIV-negative individuals
seropositive for hepatitis B surface antigen (HBsAg) (Kim et al, 2002;
Talamini et al, 2004), we also evaluated markers of HBV infection.
MATERIALS AND METHODS
Subjects
The SHCS is an ongoing study that has been enrolling PHIV since
1988, with some retrospective enrolment going back to 1984, from
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seven large hospitals in Switzerland (www.shcs.ch). Follow-up
visits take place every 6 months and clinical events, such as
opportunistic diseases, selected cancers (i.e. Kaposi’s sarcoma,
NHL, cervical cancer and Hodgkin’s lymphoma), and death have
always been recorded.
The database used for the present study included information
recorded for the SHCS up to October 2004, and has
been supplemented with independent information on cancer
occurrence from a record-linkage study between the SHCS
and eight Swiss Cantonal Cancer Registries (Clifford et al, 2005).
Cases included in the present nested case–control study were
PHIV who developed NHL, and for whom results on antibodies
against HCV (anti-HCV), or, in their absence, a blood sample
taken before NHL diagnosis (serum or plasma) to test for anti-
HCV, was available. Out of a total of 492 NHL cases identified, 77
were excluded because information on some matching criteria (see
below) was not available, and 117 because HCV serology status was
impossible to obtain. The present study finally included 298 NHL
cases (Table 1). Primary brain lymphomas (PBL) were distin-
guished from non-PBLs, and non-PBLs were classified, when
possible, by major histological subtype (i.e. diffuse large B-cell
lymphomas, Burkitt lymphomas or other) using the World Health
Organisation classification of lymphoid neoplasms (Jaffe et al,
2001).
For each NHL case three control subjects were chosen at random
among SHCS participants who had at least the same length of
follow-up as the matched-case, and for whom HCV serology, or a
blood sample to perform the test, was available. Matching criteria
were: (1) centre of enrolment in the SHCS; (2) gender; (3) age
group (in 5-year groups from 16 to 20 to X65 years); and (4)
CD4þ count (o100, 100–199, 200–499, X500 cells ml1) at
enrolment. For five control subjects, the retrieved blood sample
was inadequate for anti-HCV testing, leaving 889 control subjects
available for the present study (Table 1). Follow-up was censored
at the reference date (i.e. the date of NHL diagnosis for cases, and
the date occurring after a similar length of follow-up for matched
control subjects).
As incidence of NHL was much greater in the early part of the
SHCS and we did not match for year of enrolment, median year of
enrolment was earlier for NHL cases (1991; interquartile range:
1990– 1994) than for control subjects (1995; 1991–1998). Median
year at cancer diagnosis for NHL cases was 1995 (interquartile
range: 1993–1998).
HIV-transmission category was classified into three groups: (1)
intravenous drug users (IDUs), (2) men having sex with men
(MSM), and (3) heterosexual and others. ‘Others’ (i.e. transmission
through blood and blood products and unknown transmission
category) included only 14 NHL cases and 36 control subjects.
This study was approved by the local ethical committees of the
clinics collaborating with the SHCS and of the International
Agency for Research on Cancer. Written informed consent was
obtained from all SHCS participants.
Serology
All hepatitis virus markers were measured in blood samples taken
before NHL diagnosis or the corresponding reference date for
controls. As systematic anti-HCV testing in the SHCS started in
April 1998, anti-HCV results could not be obtained from medical
records for 172 (57.7%) NHL cases and 261 (29.4%) control
subjects. New HCV testing on stored serum aliquots was, therefore,
performed at the Institute for Medical Microbiology, University of
Basel, Switzerland using third –generation ELISA (AxSYM anti-
HCV, Abbott Diagnostic Division, Weisbaden, Germany). Reactive
results were confirmed by immunoblot. Among 51 PHIV for whom
anti-HCV results were available from both medical records and
new HCV testing, anti-HCV status agreed in 50.
Information on antibodies against hepatitis B core antigen (anti-
HBc) came from SHCS records for 100 NHL cases and 539 control
subjects. New testing was performed on stored serum aliquots
from 197 NHL cases and 347 control subjects, using microparticle
enzyme immunoassay (AxSYM core TM, Abbott Diagnostic
Division). Anti-HBc status could not be evaluated in one NHL
case and three controls whose anti-HCV status was known.
For HBsAg, information came from SHCS records for 82 NHL
cases and 472 control subjects. New testing was performed on
stored serum aliquots from 210 NHL cases and 371 control
subjects, using microparticle immunoenzyme assay (AxSYM
HBsAg version 2.0, Abbott Diagnostic Division). Hepatitis B
surface antigen status could not be evaluated in six NHL cases and
46 controls whose anti-HCV status was known.
Testing for antibodies against HBsAg and against HBe antigen
was not systematically carried out in the SHCS, and testing for
HCV RNA started only in February 2002. Thus, these three
additional viral markers were not considered in the present study.
The CD4þ count was measured by flow cytometry.
Statistical analysis
Conditional logistic regression was used to calculate odds ratios
(ORs) and corresponding 95% CIs. All analyses were conditioned
on all matching variables (see Subjects) and adjusted for HIV-
transmission category and year of enrolment (before 1990, 1990–
1995, after 1995). Additional adjustment for highly active
antiretroviral therapy (HAART) use did not substantially change
the ORs reported. Unconditional logistic regression was used for
the analyses stratified by HIV transmission category, adjusted for
all matching variables and year of enrolment.
Table 1 Distribution of 298 NHL cases and 889 control subjects
according to matching variables (Swiss HIV Cohort Study, 1984–2004)
NHL cases Control subjects
N (%) N (%)
Centre
Basel 28 (9.4) 84 (9.5)
Bern 23 (7.7) 68 (7.7)
Geneva 42 (14.1) 125 (14.1)
St Gallen 9 (3.0) 27 (3.0)
Ticino 8 (2.7) 24 (2.7)
Vaud 57 (19.1) 169 (19.0)
Zurich 131 (44.0) 392 (44.1)
Gender
Male 246 (82.6) 733 (82.5)
Female 52 (17.5) 156 (17.6)
Age at enrolment (years)
o30 83 (27.9) 249 (28.0)
30–44 141 (47.3) 425 (47.8)
X45 74 (24.8) 215 (24.2)
CD4+ at enrolment (cells ml1)
o100 71 (23.8) 209 (23.5)
100–199 47 (15.8) 142 (16.0)
200–499 120 (40.3) 357 (40.2)
X500 60 (20.1) 181 (20.4)
Duration of follow-up (months)
o24 100 (33.6) 297 (33.4)
24–59 107 (35.9) 320 (36.0)
X60 91 (30.5) 272 (30.6)
NHL¼ non-Hodgkin’s lymphoma.
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Heterogeneity of the ORs between strata of selected variables
was tested by comparing the overall maximum-likelihood estimate
for anti-HCV seropositivity to stratum-specific maximum-
likelihood estimates. The test statistic was compared to the w2
distribution with degrees of freedom equal to the number of strata
minus one (Rothman and Greenland, 1998).
RESULTS
Table 1 shows the distribution of NHL cases and control subjects
by matching variables. Among the seven SHCS centres, Zurich
alone contributed 44% of study participants. The majority of study
participants were male (83%) and 48% were between 30 and 44
years of age. Forty per cent had a CD4þ count at enrolment below
200 cells ml1, and in 31% follow-up before the reference date was
60 months or longer (Table 1).
Figure 1 shows seropositivity for the three hepatitis virus
markers by HIV transmission category among control subjects.
Anti-HCV was detected in 95.0% of IDUs, 3.9% of MSM and 14.6%
of heterosexuals and other. Seropositivity for anti-HBc was nearly
as frequent as seropositivity for anti-HCV among IDUs, but
substantially higher than anti-HCV among MSM (65.3%) and
heterosexuals and other (49.6%). Seropositivity for HBsAg was
found in 7.2% of IDUs, 8.4% of MSM and 3.2% of heterosexuals
and other.
None of the three hepatitis virus markers considered showed an
association with NHL risk (Table 2). ORs were 1.05 (95% CI: 0.63–
1.75) for anti-HCV, 0.85 (95% CI: 0.61–1.18) for anti-HBc and 0.62
(95% CI: 0.32–1.20) for HBsAg seropositivity.
Table 3 shows the influence of anti-HCV seropositivity on NHL
risk in separate strata of CD4þ count at enrolment, age, gender
and HIV transmission category. Anti-HCVþ PHIV did not show
an increased NHL risk compared to anti-HCV PHIV in any
separate stratum except for HIV transmission category, where a
significant association between anti-HCV and NHL risk emerged
among MSM (OR¼ 2.37; 95% CI: 1.03–5.43). In no instance,
however, was the effect of anti-HCV seropositivity on NHL risk
significantly heterogeneous across the strata of the variables
considered (Table 3).
Seropositivity for anti-HBc and HBsAg was not associated with
NHL risk in any stratum of CD4þ count at enrolment, age, gender
or HIV-transmission category (data not shown).
Figure 2 shows the percent distribution of CD4þ count at
lymphoma diagnosis and NHL subtype separately among anti-
HCVþ and anti-HCV NHL cases. Although 95% CIs always
overlapped, a slightly lower proportion of anti-HCVþ than anti-
HCV NHL cases had less than 50 CD4þ cells ml1 at cancer
diagnosis (26.0 vs 35.9%, respectively), or were diagnosed with PBL
(19.0 vs 25.8%, respectively).
DISCUSSION
Seropositivity for HBV and HCV did not increase NHL risk among
PHIV in the SHCS. Our findings on HCV, the most studied
hepatitis virus in respect to NHL risk (Dal Maso and Franceschi, in
press), are consistent with previous studies of PHIV that also did
not show an association (Besson et al, 1999; Levine et al, 1999;
Waters et al, 2005). Compared to earlier reports on the topic, our
study was, however, much larger, allowing stratification by, and
more accurate allowance for, other correlates of NHL risk.
As expected, levels of seropositivity for hepatitis viruses were
high among PHIV, most notably among IDUs. The higher anti-
HBc/anti-HCV seropositivity ratio among MSM (16.7) and
heterosexuals and other (3.4) compared to IDUs (0.90) confirms
the much greater efficiency of the sexual-route of transmission for
HBV than HCV (IARC, 1994).
We were not able to review the slides of NHL cases, and
histological type was not specified in 43% of the cases, thus
limiting the chance of detecting qualitative differences between
anti-HCVþ and anti-HCV lymphomas. We did detect, however, a
slight under-representation of anti-HCVþ compared to anti-
HCV cases among NHL occurring at CD4þ counts below
50 cells ml1 and among PBL, which are the two lymphoma
subtypes where EBV is known to be most strongly implicated
(Jaffe et al, 2001). Among transplant patients, for instance, the
majority of NHL is associated with EBV, but NHL has also been
reported in EBV patients and tends to occur longer after organ
transplant, when immunosuppression is milder, than in EBVþ
patients (Leblond et al, 2001).
As among transplant patients, the strong role of immunodefi-
ciency and EBV in NHL (Jaffe et al, 2001) makes the evaluation of
possible weak risk factors such as HCV infection much more
difficult among PHIV than in the general population (Negri et al,
2004). A hint of an association between NHL risk and HCV
HIV transmission category
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Figure 1 Seropositivity for antibodies against hepatitis C virus (anti-
HCV), anti-HBc and hepatitis B surface antigen (HbsAg) in control subjects
by HIV-transmission category. Swiss HIV Cohort Study, 1984–2004. IDU:
intravenous drug users; MSM: men having sex with men.
Table 2 ORs and corresponding 95% CIs for NHL by presence of
hepatitis virus markers (Swiss HIV Cohort Study, 1984–2004)
NHL cases Control subjects
Seropositivity N (%) N (%) OR (95% CI)a
Anti-HCV
No 198 (66.4) 605 (68.1) 1b
Yes 100 (33.6) 284 (32.0) 1.05 (0.63–1.75)
Anti-HBc
No 101 (34.0) 305 (34.4) 1b
Yes 196 (66.0) 581 (65.6) 0.85 (0.61–1.18)
HBsAg
No 279 (95.6) 790 (93.7) 1b
Yes 13 (4.5) 53 (6.3) 0.62 (0.32–1.20)
Anti-HCV¼ antibodies against hepatitis C virus; anti-HBc¼ antibodies against
hepatitis B core antigen; HBsAg¼ antibodies against hepatitis B surface antigen;
NHL¼ non-Hodgkin’s lymphoma; OR¼ odds ratios; CI¼ confidence intervals.
aEstimated from conditional logistic regression analysis, conditioned on centre,
gender, age group, and CD4+ count at enrolment and adjusted for HIV-transmission
category and year of enrolment. bReference category.
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infection emerged among MSM, who had lower levels of anti-HCV
seropositivity than heterosexuals and IDUs. Indeed, nearly all
IDUs were anti-HCVþ , thus preventing any meaningful evaluation
of the effect of HCV infection on NHL risk. Furthermore,
MSM (median age 38) were older than subjects in the
other HIV-transmission categories (median age 31 and 35 for
IDUs and heterosexuals and other, respectively). A two-fold
increased NHL risk was also found among anti-HCVþ PHIV
aged 45 years or older, although it did not reach statistical
significance. Older age may be a correlate of longer exposure to
HCV, and, hence, higher risk of HCV-related complications
including NHL. Indeed, the relative risk for cirrhosis in anti-
HCVþ vs anti-HCV PHIV increased between the pre-HAART
and HAART era (Giordano et al, 2004) and the excess of
hepatocellular carcinoma currently seen in PHIV (Clifford et al,
2005) had not clearly emerged earlier in the epidemic (Beral and
Newton, 1998).
An important strength of the SHCS is the fact that it is very
representative of PHIV in Switzerland. It has been estimated that,
since the beginning of the HIV epidemic, 48% of PHIV, and 68% of
people diagnosed with AIDS in Switzerland have been enrolled in
the SHCS (www.shcs.ch). Weaknesses of the SHCS include
incomplete information on time of HIV seroconversion, which
prevented us from using years of follow-up as an exact proxy for
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Figure 2 Comparison of percent distribution of CD4þ counts at NHL
diagnosis (A) and NHL subtype (B) between 100 anti-HCVþ and 198
anti-HCV NHL cases. Swiss HIV Cohort Study, 1984–2004. Anti-HCV:
antibodies against hepatitis C virus; PBL: Primary brain lymphoma; DLBC:
diffuse large B-cell NHL. ‘Unknown’ refers to no CD4þ count result within
6 months before cancer diagnosis.
Table 3 ORs and corresponding 95% CIs for NHL by presence of anti-
HCV in strata of selected matching variables and HIV-transmission category
(Swiss HIV Cohort Study, 1984–2004)
NHL cases Control subjects
N (%) N (%) OR (95% CI)a
CD4+ at enrolment (cells ml1)
o100
Anti-HCV 54 (76.1) 152 (72.7) 1b
Anti-HCV+ 17 (23.9) 57 (27.3) 1.47 (0.47–4.53)
100–199
Anti-HCV 23 (48.9) 96 (67.6) 1b
Anti-HCV+ 24 (51.1) 46 (32.4) 2.04 (0.67–6.20)
200–499
Anti-HCV 83 (69.2) 240 (67.2) 1b
Anti-HCV+ 37 (30.8) 117 (32.8) 0.64 (0.26–1.60)
X500
Anti-HCV 38 (63.3) 117 (64.6) 1b
Anti-HCV+ 22 (36.7) 64 (35.4) 1.06 (0.36–3.15)
Test for heterogeneity w3
2¼ 1.49; P¼ 0.68
Age group (years)
o30
Anti-HCV 50 (60.2) 136 (54.6) 1b
Anti-HCV+ 33 (39.8) 113 (45.4) 0.62 (0.24–1.62)
30–44
Anti-HCV 82 (58.2) 267 (62.8) 1b
Anti-HCV+ 59 (41.8) 158 (37.2) 1.04 (0.49–2.21)
X45
Anti-HCV 66 (89.2) 202 (94.0) 1b
Anti-HCV+ 8 (10.8) 13 (6.1) 2.21 (0.73–6.70)
Test for heterogeneity w2
2¼ 1.56; P¼ 0.46
Gender
Female
Anti-HCV 26 (50.0) 88 (56.4) 1b
Anti-HCV+ 26 (50.0) 68 (43.6) 1.07 (0.34–3.31)
Male
Anti-HCV 172 (69.9) 517 (70.5) 1b
Anti-HCV+ 74 (30.1) 216 (29.5) 1.05 (0.59–1.87)
Test for heterogeneity w1
2¼ 0.00; P¼ 0.98
HIV-transmission category
Intravenous drug users
Anti-HCV 6 (7.5) 12 (5.0) 1b
Anti-HCV+ 74 (92.5) 227 (95.0) 0.37 (0.11–1.22)c
Men having sex with men
Anti-HCV 132 (90.4) 341 (96.1) 1b
Anti-HCV+ 14 (9.6) 14 (3.9) 2.37 (1.03–5.43)c
Heterosexuals and others
Anti-HCV 60 (83.3) 252 (85.4) 1b
Anti-HCV+ 12 (16.7) 43 (14.6) 1.02 (0.44–2.36)c
Test for heterogeneity w2
2¼ 3.34; P¼ 0.19
anti-HCV¼ antibodies against hepatitis C virus; HIV¼ human immunodeficiency
virus; NHL¼ non-Hodgkin’s lymphoma; OR¼ odds ratios; CI¼ confidence intervals.
aEstimated from conditional logistic regression analysis, conditioned on centre,
gender, age group, and CD4+ count at enrolment and adjusted for HIV-transmission
category and year of enrolment; bReference category. cEstimated from unconditional
logistic regression analysis, adjusted as in footnote a.
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duration of HIV infection. In addition, no information was
available on EBV infection and on the activity of HCV infection,
that is the presence of serum HCV RNA. The vast majority of
persons acutely infected with HCV develop chronic persistent
viraemia and, especially among PHIV, anti-HCV seropositivity is
likely to correspond to chronic HCV infection (Sulkowski et al,
2000).
In conclusion, coinfection with HIV and HCV or HBV did not
increase NHL risk compared to HIV alone in the SHCS. However,
as the life expectancy of PHIV increases, the influence of HCV
infection on cancer risk deserves further study as the high
prevalence of HCV could result in huge attributable risks, even in
the presence of weak relative risks.
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